Moneycontrol PRO

Subscribe to Mankind Pharma: ICICI Direct

ICICI Direct has come out with its report on Mankind Pharma. The research firm has recommended to “ Subscribe ” the ipo in its research report as on April 24, 2023.

April 25, 2023 / 09:45 AM IST


  • bselive
  • nselive
Todays L/H

ICICI Direct IPO report on Mankind Pharma

Established in 1991, Mankind Pharma Ltd (Mankind) is a leading India-focused formulation player deriving ~98% of its total sales from branded formulations. Mankind is the fourth largest player in the domestic market with a presence across therapy areas like anti-infectives, cardiac, gastro, respiratory and also in consumer healthcare segments like condoms, acne preparations, emergency contraceptives, pregnancy tests among others • As of December 2022, it employed 4,121 manufacturing workers across 25 manufacturing locations, four R&D laboratories in India. It has a field team of 3,561 field managers and 11,691 medical representatives across India.

Valuation and Outlook

We assign SUBSCRIBE rating on the back of 1) opportunities from its newer acquired products and its plan to backward integrate in its power brands, 2) Structural preference for domestic branded formulations among broader healthcare themes .

For all IPO report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

24042023 - Mankind Pharma -IPO - Icici

Broker Research